All the news

London needs to step up the rate of testing for hepatitis C if it is to achieve elimination of hepatitis C, Professor Graham Foster of Queen Mary University London told the London ...

Intensive peer support during engagement with hepatitis C care was associated with a high level of engagement in care among vulnerable people including recently homeless people and people who inject drugs in London, ...

Hepatitis C screening programmes targeting the homeless, people who inject drugs and prisoners achieved linkage to specialist care in over 80% of people diagnosed with hepatitis C, a four-country European study found. The study ...

Increasing the frequency of hepatitis C screening in gay and bisexual men taking pre-exposure prophylaxis (PrEP) in the United Kingdom has the potential to reduce new hepatitis C infections in ...

A healthy lifestyle, including smoking cessation, moderate drinking, a balanced diet, exercise and weight loss could dramatically reduce the growing burden of liver cancer and deaths due to liver disease, according to a study ...

Combination regimens using lonafarnib or bulevirtide reduced levels of hepatitis delta virus (HDV) in a majority of people with HDV and hepatitis B virus (HBV) co-infection, researchers reported at the AASLD Liver Meeting ...

All adults in the United States should be screened for hepatitis C by healthcare providers as part of routine medical care, updated guidelines from the American Association for the Study of Liver ...

Non-alcoholic fatty liver disease is a growing cause of liver cancer and death in some regions of the world, an analysis of global reporting on liver disease shows. The findings ...

A combination of nivolumab (Opdivo) and ipilimumab (Yervoy), two different types of checkpoint inhibitor immunotherapy, led to higher response rates and longer survival than nivolumab alone in people with advanced liver cancer, according to a ...

Phase II study results presented at the AASLD Liver Meeting this month in Boston show that a number of experimental therapies improve markers of liver health in people with non-alcoholic steatohepatitis (NASH). ...